Clinical trials
Therapy clinical trials
Below are recruiting therapy clinical trials, each written for real people, not researchers. We’re tracking 7,377 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07188350Recruiting
Electrical muscle stimulation for patients on a breathing machine
This trial tests whether low-level electrical pulses to the leg muscles can help prevent weakness in patients who need a breathing tube (ventilator) for more than 48 hours. It aims to see if this treatment helps patients recover faster.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT07184684RecruitingPhase 2/Phase 3
Nasal bacteria transplant for chronic sinusitis
This trial tests if transplanting healthy nasal bacteria from a donor can help people with chronic sinusitis. It aims to restore a healthy microbiome in the nose to reduce symptoms like congestion and discharge.
HelsingborgAges 18 years+ - NCT07185802Recruiting
PRP injection for recent ACL injury
This trial tests whether a shot of your own concentrated platelets (PRP) into the knee improves healing after a recent ACL injury. It's for people with mild to moderate ACL tears and no major other knee damage.
DhakaAges 18–50 - NCT06546150RecruitingPhase 1
Cell therapy for KRAS G12V mutated advanced solid tumors
This trial tests a new immune cell therapy (called RE002 T cells) for people with advanced solid tumors that have a specific KRAS G12V mutation and a certain HLA type. The therapy is designed to target and attack cancer cells that carry this mutation.
Zhengzhou, HenanAges 18–75 - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+ - NCT06414759RecruitingPhase 4
Combination diuretic therapy for heart failure fluid overload
This trial tests a combination of water pills (diuretics) to help remove extra fluid in people hospitalized with acute decompensated heart failure (sudden worsening of heart failure). It aims to find a safe and effective way to reduce swelling and fluid buildup.
Giza, GZAges 18–65 - NCT07167641Recruiting
Support for parents and caregivers of young people with psychosis
This study focuses on supporting parents and caregivers of young people who have had a first episode of psychosis. The goal is to understand how to help you while you care for your loved one. If you’re a caregiver connected to a UNC Coordinated Specialty Care program, you may be able to join.
Chapel Hill, North CarolinaAges 18–99 - NCT06549907Recruiting
Study of double immunotherapy plus anti-angiogenic therapy
This trial studies people with certain types of colorectal or other solid tumors that did not respond to a single immunotherapy drug. It tests whether adding a second immune checkpoint blocker and an anti-angiogenic drug can help control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05548244Recruiting
Testing behavioral activation for teens with depression
This study looks at how a therapy approach called behavioral activation may affect depression in teens. It also uses brief daily check-ins on a phone to understand what changes during treatment.
Atlanta, GeorgiaAges 15–17 - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT06974123Enrolling by invitationPhase 1/Phase 2
Testing a new oral drug for radiation proctitis
This trial tests an oral drug called Teslanbaicin for people who have pelvic cancer and developed radiation proctitis (inflammation of the rectum from radiation therapy). The goal is to see if it is safe and helps heal the inflammation.
Xinxiang, HenanAges 18 years+ - NCT07147426RecruitingPhase 2
Tislelizumab plus chemo before surgery for head and neck cancer
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07143929RecruitingPhase 1
CD7-targeted CAR-T therapy for relapsed or refractory peripheral T-cell lymphoma
This trial tests a new type of immunotherapy called CAR-T that targets a protein called CD7 on cancer cells. It is for people with peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
BeijingAges 18–80 - NCT05585684Recruiting
Blood test to guide next cancer treatment choices
This study checks whether a blood test can find tumor genetic changes (called “plasma genomic profiling”) to help choose the best next treatment. It may help your care team decide therapy after your cancer progresses or seems likely to progress soon.
Baltimore, MarylandAges 18 years+ - NCT04656041RecruitingPhase 2
Test chemo with radiation for gastroesophageal cancer
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
Boston, MassachusettsAges 18 years+ - NCT07128420Enrolling by invitationPhase 1
Microneedling for chronic Peyronie's disease: a pilot study
This pilot study tests whether microneedling (tiny needles used on the skin) can safely and effectively reduce the curve caused by Peyronie's disease. If you have had a stable curve for at least 6 months and have not tried other treatments recently, you may be able to join.
Ottawa, OntarioAges 18 years+ - NCT07115667RecruitingPhase 2
Radiation and antibody therapy for bone plasmacytoma
This trial tests a new combination of radiation therapy and a bispecific antibody (a drug that helps your immune system attack cancer cells) for people with a single bone plasmacytoma that has only a small number of abnormal cells in the bone marrow. It aims to see if this approach can control the disease better than radiation alone.
TianjinAges 18–78 - NCT06835725RecruitingPhase 2
Comparing two prostate radiation schedules for intermediate risk
This trial compares giving radiation in 2 treatments versus 5 treatments for prostate cancer that hasn't spread. It's for men with low or intermediate risk prostate cancer who are healthy enough to undergo a short course of targeted radiation.
Surrey, British ColumbiaAges 18 years+ - NCT06563141Recruiting
Rehabilitation program for C-shaped scoliosis
This study tests a specific rehabilitation program for people with a C-shaped spine curve (scoliosis) that is mild to moderate (10–30 degrees). The program aims to improve posture and reduce the curve without surgery.
CairoAges 18–30 - NCT05640791RecruitingPhase 2
Durvalumab with chemo before surgery for bile duct cancer
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT07097935RecruitingPhase 1/Phase 2
Study of HS-10516 combo therapy for advanced kidney cancer
This trial tests a new combination therapy for people with advanced clear cell kidney cancer that has progressed after at least one prior treatment. It aims to see if adding HS-10516 to standard care can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07231458RecruitingPhase 1
Testing a new immunotherapy with pembrolizumab for advanced solid tumors
This trial tests ABX-001, a new immunotherapy, alone or with pembrolizumab, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. It may help if your tumor has become resistant to previous immunotherapies.
BerlinAges 18 years+ - NCT07284836RecruitingPhase 2
Chemo directly to liver for breast cancer
This trial tests a new way to give chemotherapy directly to the liver for breast cancer that has spread only there. It's for people who have already tried two or more standard treatments.
Hangzhou, ZhejiangAges 18–70 - NCT07064551Recruiting
Combining medical and community support for depression
This study tests a new way of combining medical care with community support for middle-aged and older adults who have depression and are waiting for mental health services. The goal is to see if this team approach can help improve mood and well-being while you wait.
Hong KongAges 45 years+
Hear when a new Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for therapy?
- Yes. Clin2 currently lists 7,377 recruiting therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.